The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease

被引:16
作者
Tashkin, D. P. [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA
关键词
aclidinium; anticholinergic bronchodilators; drug safety; glycopyrronium; ipratropium; tiotropium; umeclidinium; DAILY ACLIDINIUM BROMIDE; ACTING MUSCARINIC ANTAGONIST; ACUTE URINARY RETENTION; INHALED GLYCOPYRRONIUM; CARDIOVASCULAR SAFETY; BETA-AGONISTS; COPD PATIENTS; DOUBLE-BLIND; MU-G; TIOTROPIUM;
D O I
10.1517/14740338.2015.1093621
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Poorly absorbable quaternary ammonium-inhaled muscarinic antagonists both as the short-acting ipratropium and as long-acting (12 - 24 h) agents (tiotropium, glycopyrronium, aclidinium and umeclidinium) have all demonstrated statistically and clinically significant efficacy in chronic obstructive pulmonary disease compared with placebo. However, controversy has arisen concerning the safety of this class of agents principally regarding their association with both fatal and nonfatal cardiovascular toxicity. Areas covered: The safety of both ipratropium and the long-acting muscarinic antagonists is reviewed with a major emphasis on potential cardiovascular toxicity, based on published clinical trials data and results of analyses of pooled data, meta-analyses, and observational studies. Since glycopyrronium, aclidinium, and umeclidinium have become available only relatively recently, more emphasis will be placed on the more extensive literature concerning the safety of the older anticholinergic compounds, the short-acting ipratropium, and the long-acting tiotropium in its dry powder formulation, as well as its newer soft mist inhaler delivery device. Expert opinion: Pooled analyses and meta-analyses of randomized controlled trials (RCTs) of tiotropium in both its dry powder and soft mist formulations, as well as some observational studies, have implicated this agent as increasing the risk of nonfatal and fatal cardiovascular events. However, the most robust evidence based on large-scale randomized controlled trials (RCTs) of relatively long duration specifically designed to evaluate the cardiovascular safety of tiotropium have not confirmed these safety concerns. Because of the relatively limited amount of safety data for the newer long-acting muscarinic antagonists compared to the far more extensive experience with tiotropium, it will be important to accumulate additional safety information from post-marketing pharmacovigilance for these newer agents.
引用
收藏
页码:1759 / 1772
页数:14
相关论文
共 89 条
  • [1] Afonso ASM, 2010, BJUI, V107, P265
  • [2] [Anonymous], 2015, GLOB STRAT DIAGN MAN
  • [3] [Anonymous], COCHRANE DATABASE SY
  • [4] [Anonymous], STAND DIAGN MAN PAT
  • [5] Hospitalizations and mortality in the Lung Health Study
    Anthonisen, NR
    Connett, JE
    Enright, PL
    Manfreda, J
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (03) : 333 - 339
  • [6] EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY
    ANTHONISEN, NR
    CONNETT, JE
    KILEY, JP
    ALTOSE, MD
    BAILEY, WC
    BUIST, AS
    CONWAY, WA
    ENRIGHT, PL
    KANNER, RE
    OHARA, P
    OWENS, GR
    SCANLON, PD
    TASHKIN, DP
    WISE, RA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19): : 1497 - 1505
  • [7] The role of anticholinergics in chronic obstructive pulmonary disease
    Barnes, PJ
    [J]. AMERICAN JOURNAL OF MEDICINE, 2004, 117 : 24S - 32S
  • [8] MUSCARINIC RECEPTOR SUBTYPES IN AIRWAYS
    BARNES, PJ
    [J]. LIFE SCIENCES, 1993, 52 (5-6) : 521 - 527
  • [9] Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis
    Barr, R. G.
    Bourbeau, J.
    Camargo, C. A.
    Ram, F. S. F.
    [J]. THORAX, 2006, 61 (10) : 854 - 862
  • [10] A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients
    Bateman, E. D.
    Tashkin, D.
    Siafakas, N.
    Dahl, R.
    Towse, L.
    Massey, D.
    Pavia, D.
    Zhong, N. S.
    [J]. RESPIRATORY MEDICINE, 2010, 104 (10) : 1460 - 1472